Suomi - suomi - Fimea (Suomen lääkevirasto)

avansor pharma oy - lenalidomide - kapseli, kova - 7.5 mg - lenalidomidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

avansor pharma oy - lenalidomide - kapseli, kova - 10 mg - lenalidomidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

avansor pharma oy - lenalidomide - kapseli, kova - 15 mg - lenalidomidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

avansor pharma oy - lenalidomide - kapseli, kova - 20 mg - lenalidomidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

avansor pharma oy - lenalidomide - kapseli, kova - 25 mg - lenalidomidi

Euroopan unioni - suomi - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; lymphoma, follicular - immunosuppressantit - multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on tarkoitettu aikuisille potilaille, joilla on aiemmin hoitamaton multippeli myelooma, jotka eivät ole oikeutettuja siirto. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka d. novo mesto as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka d. novo mesto as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) on tarkoitettu aikuisille potilaille, joilla on aiemmin hoitamaton multippeli myelooma, jotka eivät ole oikeutettuja siirto. lenalidomide krka d. novo mesto in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide krka d. novo mesto in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Euroopan unioni - suomi - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastiset aineet - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Euroopan unioni - suomi - EMA (European Medicines Agency)

amgen europe b.v. - carfilzomib - multiple myeloma - antineoplastiset aineet - kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Suomi - suomi - Fimea (Suomen lääkevirasto)

sandoz a/s - lenalidomide - kapseli, kova - 2.5 mg - lenalidomidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

sandoz a/s - lenalidomide - kapseli, kova - 5 mg - lenalidomidi